SCHEDULE: Vanguard Group Reports 0% Stake in Kura Oncology
Beneficial Ownership Amendment
The Vanguard Group has filed an amended Schedule 13G, reporting a 0% beneficial ownership in Kura Oncology Inc. following an internal realignment.
Summary
- The Vanguard Group filed an Amendment No. 2 to Schedule 13G regarding its beneficial ownership of Common Stock in Kura Oncology Inc.
- As of the event date March 13, 2026, The Vanguard Group reported 0% beneficial ownership of Kura Oncology Inc. common stock.
- This change is due to an internal realignment at The Vanguard Group, Inc. on January 12, 2026.
- Certain subsidiaries or business divisions of The Vanguard Group, Inc. will now report beneficial ownership separately (on a disaggregated basis).
- The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral administrative filing. It clarifies Vanguard's reporting structure but does not reflect a change in investment thesis for Kura Oncology Inc. by Vanguard's underlying funds.
Future Outlook
No forward-looking statements or guidance for Kura Oncology Inc. are provided in this administrative filing.
Industry Context
StockSavvy.ai notes that such Schedule 13G amendments are common for large institutional investors like The Vanguard Group, especially following internal reorganizations or when their beneficial ownership reporting structure changes. This particular filing reflects an administrative change in how Vanguard's various entities report their holdings, rather than a strategic divestment of Kura Oncology Inc. shares by all Vanguard-managed funds.
Stakeholder Impact
- Shareholders: Existing shareholders of Kura Oncology Inc. should understand that this 0% reporting by the parent Vanguard Group is due to an internal administrative change, not necessarily a complete divestment by all Vanguard-managed funds. The actual aggregate holdings by Vanguard's various funds may still be significant, but will now be reported disaggregated.
Key Dates
| Date | Description |
|---|---|
| 1998-01-12 | Date of SEC Release No. 34-39538, referenced for disaggregated reporting. |
| 2026-01-12 | Date of internal realignment at The Vanguard Group, Inc. |
| 2026-03-13 | Date of event which requires filing of this statement (beneficial ownership change). |
| 2026-03-27 | Date the Schedule 13G/A was signed by The Vanguard Group. |
Recommendation
holdThis filing is purely administrative, detailing a change in how The Vanguard Group reports its beneficial ownership due to an internal realignment. It does not provide any new information regarding Kura Oncology Inc.'s operational performance, financial health, or strategic outlook. Therefore, it offers no basis for a change in investment recommendation for Kura Oncology Inc. An investor should hold their position and await more substantive company-specific news.
Keywords
Kura Oncology Inc, Vanguard Group, Schedule 13G, Beneficial Ownership, SEC Filing, Institutional Ownership, Common Stock, Corporate Realignment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.